Global Virus Network Backs Moderna H5N1 Vaccine Trials Amid Rising Avian Flu Threats

The Global Virus Network endorses mRNA H5N1 vaccine trials as avian flu cases rise and human spillover events in Cambodia show a 40 percent fatality rate.

By: AXL Media

Published: Apr 28, 2026, 8:39 AM EDT

Source: Information for this report was sourced from EurekAlert

Accelerating Vaccine Momentum in Response to Viral Evolution

The Global Virus Network (GVN), a coalition of virologists spanning more than 40 countries, has expressed strong support for the recent acceleration in H5N1 avian influenza vaccine research. Central to this momentum is the launch of a Phase 3 clinical trial for Moderna’s mRNA based vaccine candidate, mRNA-1018, which is being conducted primarily in the United Kingdom and the United States. According to Marion Koopmans, a director at a GVN center of excellence, the virus is consistently expanding both its geographic reach and its host range. This shift necessitates a rapid acceleration of preparedness measures to ensure that scientific defenses keep pace with the evolving biological threat.

Surveillance Data Reveals Unprecedented Avian Infection Levels

Recent environmental and veterinary reports indicate that the scale of H5N1 spread in the animal kingdom has reached alarming proportions. Between November 2025 and February 2026, European authorities documented over 2,500 detections of highly pathogenic avian influenza across 32 nations. Data from the European Food Safety Authority suggests that these levels are significantly higher than those observed in previous years, with the vast majority of cases occurring in wild bird populations. The GVN notes that while human to human transmission has not yet been observed, the sustained presence of the virus in mammals and wild birds creates a credible risk for a future pandemic.

Monitoring High Fatality Rates in Human Spillover Events

The risks associated with the human animal interface are currently most visible in Cambodia, where sporadic zoonotic transmission continues to cause severe illness. Since 2023, the country has reported more than 30 human cases of H5N1, with a case fatality rate exceeding 40 percent. Reports indicate that multiple human infections have already been documented in 2026, underscoring the lethal potential of the virus when it successfully jumps to humans. These spillover events serve as a primary catalyst for the GVN's call to integrate real time genomic surveillance with vaccine planning to protect global health.